Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

29.76
+1.374.83%
Post-market: 29.810.0542+0.18%19:56 EDT
Volume:2.46M
Turnover:72.85M
Market Cap:3.07B
PE:-35.53
High:30.50
Open:28.74
Low:28.61
Close:28.39
52wk High:38.26
52wk Low:16.02
Shares:103.29M
Float Shares:91.60M
Volume Ratio:1.31
T/O Rate:2.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8376
EPS(LYR):-0.8100
ROE:-8.18%
ROA:-17.01%
PB:2.88
PE(LYR):-36.74

Loading ...

Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)

TIPRANKS
·
Mar 16

H.C. Wainwright Keeps Their Buy Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
Mar 10

Beam Therapeutics Inc - on March 2, Co and Bio Palette Mutually Terminate License Agreement Dated March 27, 2019 - SEC Filing

THOMSON REUTERS
·
Mar 06

Assessing Beam Therapeutics (BEAM) Valuation After Q4 Earnings Surprise Credit Facility And PKU Program Launch

Simply Wall St.
·
Feb 28

Beam Therapeutics President Giuseppe Ciaramella Disposes of Common Shares

Reuters
·
Feb 27

Stock Track | Beam Therapeutics Soars 5.23% Intraday on Analyst Upgrades

Stock Track
·
Feb 25

Clear Street Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
Feb 25

U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP

Reuters
·
Feb 25

What's Going On With Beam Therapeutics Stock?

Benzinga_recent_news
·
Feb 25

Beam Therapeutics announces $500M financing facility

TIPRANKS
·
Feb 24

Beam Therapeutics Secures $500 Million Credit Facility

TIPRANKS
·
Feb 24

Earnings Flash (BEAM) Beam Therapeutics Posts Q4 EPS $2.33, vs. FactSet Est of $1.01 Loss

MT Newswires Live
·
Feb 24

Beam Therapeutics tops Q4 profit estimates, signs financing deal

Reuters
·
Feb 24

Beam Q4 net income attributable to common stockholders hits USD 244.3 million

Reuters
·
Feb 24

Beam Therapeutics Secures $500 Million Financing Facility With Sixth Street

Reuters
·
Feb 24

Beam Therapeutics Inc - Secures up to $500 Mln Non-Dilutive Capital From Sixth Street

THOMSON REUTERS
·
Feb 24

Beam Therapeutics Inc - Plans Ind Filing for Beam-304 With FDA in 2026

THOMSON REUTERS
·
Feb 24

Beam Therapeutics Q4 License and Collaboration Revenue USD 114.109 Million

THOMSON REUTERS
·
Feb 24

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

GlobeNewswire
·
Feb 24

Beam Therapeutics Inc - Credit Facility Matures in 2033 With 10% Interest Rate

THOMSON REUTERS
·
Feb 24